设为首页 加入收藏

当前位置: 学院首页 > 招生就业 > 研究生招生 > 医学生物化学与分子生物学专业硕导简介 > 正文

黄盼盼导师简介

作者:时间:2026-09-14点击数:

    黄盼盼,女,副教授,硕士生导师,2020年毕业于浙江大学医学院,获得病理学与病理生理学博士学位。研究方向为肿瘤学,主要研究乳腺癌和胃癌的发生发展机制,近5年以第一作者或通讯作者发表高水平SCI论文10余篇。主持国家自然科学基金2项,参与国家自然科学基金3项,主持江西省自然科学科学基金1项,横向课题1项。Translational Oncology期刊优秀审稿人。指导学生参加全国大学生医学创新大赛暨“一带一路”国际竞赛获全国金奖1项、铜奖2项,指导大学生创新创业训练国家级项目立项2项、省级项目立项2项,指导学生获得学校科技创新项目自然类一等奖2项,指导学生以第一作者发表SCI论文6篇。指导硕士研究生5人,其中3人在读,2人已毕业(1人读博)。

   

欢迎感兴趣的同学联系!

         电话:15705810004       Email: huangpp@gmu.edu.cn

近年主持科研项目:

(1) 国家自然科学基金青年基金项目,82202928,PLSCR1激活EGFR-MAPK信号通路促进三阴性乳腺癌耐药的作用与机制研究。

(2) 国家自然科学基金地区基金项目,82560532,Lumican通过调控糖酵解抑制巨噬细胞M2型极化逆转TNBC化疗耐药的机制研究。

(3) 江西省自然科学面上基金项目,20232BAB206111,亚砷酸通过干扰AGS8-VEGFR2-Gβγ复合体的形成抑制胃癌进展的机制研究。

(4) 横向课题项目,HX202414,胃癌特异性新抗原预测、筛选、鉴定及作用机制研究。

近年以第一作者或通讯作者发表的代表性论文:

(1) Lu Yao, Zeng Xueliang, Peng Shixiong, Zhan Yang, Liu Wenyu, Zhao Rui, Li Jing, Huang Qiang, Ye Tingting, Yuan Zixuan, Huang Panpan*. PLSCR1 drives chemoresistance in TNBC via METTL3/IGF2BP3-mediated mRNA stabilization and EGFR-MAPK pathway activation. Cell death & disease, 2026, 17(1):624.

(2) Huang Panpan, Liao Ruocen, Chen Xingyu, Wu Xuebiao, Li Xiaoli, Wang Yifan, Cao Qianhua, Dong Chenfang. Nuclear translocation of PLSCR1 activates STAT1 signaling in basal-like breast cancer. Theranostics, 2020, 10(10): 4644-4658.

(3) Lu Yao, Song Tao, Xue Xue, Cao Gaolu, Huang Panpan*. Kinesin superfamily proteins: roles in osteosarcoma. Frontiers in Bioscience-Landmark, 2021, 26(8): 370-378.

(4) Lu Yao, Cao Gaolu, Lan Haiying, Liao Hua, Hu Yaqiong, Feng Haihua, Liu, Xiaojian, Huang Panpan*. Chondrocyte-derived Exosomal miR-195 Inhibits Osteosarcoma Cell Proliferation and Anti-Apoptotic by Targeting KIF4A in vitro and in vivo. Translational Oncology, 2021, 16: 101289.

(5) Liu Wenyu, Li Jing, Zhao Rui, Lu Yao, Huang Panpan*. The Uridine diphosphate (UDP)-glycosyltransferases (UGTs) superfamily: the role in tumor cell metabolism. Front Oncol, 2023, 12:1088458.

(6) Wang Yigang#, Huang Panpan#, Hu Yanping, Guo Keni, Jia Xiaoyuan, Huang Biao, Liu Xinyuan, He Xianglei, Huang Fang. An oncolytic adenovirus delivering TSLC1 inhibits Wnt signaling pathway and tumor growth in SMMC-7721 xenograft mice model. Acta Biochim Biophys Sin, 2021, 53(6): 766-774.

(7) Lu Yao#, Huang Panpan#, Li Yanli, Liu Wenyu, Li Jing, Zhao Rui, Feng Haihua, Shi Ce, Cao Gaolu. The FBXO32/ATR/ATM axis acts as a molecular switch to control the sensitivity of osteosarcoma cells to irradiation through its regulation of EXO1 expression. Acta Biochim Biophys Sin, 2023, 55(5):842-852.

(8) Lu Yao#, Huang Panpan#, Zeng Xueliang, Liu Wenyu, Zhao Rui, Li Jing, Cao Gaolu, Hu Yaqiong, Xiao Qiuxiang, Wu Meng, Huang Weicai, Tang Xuerui, Liu Xiaojian, Wei Hulai. Inhibition of FNDC1 suppresses gastric cancer progression by interfering with Gβγ-VEGFR2 complex formation. iScience, 2023, 26(9):107534.

(9) Huang Weicai, Liu Wenyu, Yu Tingting, Zhang Zhaoyang, Zhai Lingyun, Huang Panpan*, Lu Yao*. Effect of anti-COVID-19 drugs on patients with cancer. European journal of medicinal chemistry, 2024, 268:116214.

(10) Wang Yuxuan, Liu Zhiwei, Lv Yulu, Long Jiayang, Lu Yao, Huang Panpan*. Mechanisms of radioresistance and radiosensitization strategies for Triple Negative Breast Cancer. Translational oncology, 2025, 55:102351.

(11) Tang Xuerui, Lu Llizhi, Li Xiaoping, Huang Panpan*. Bridging Cancer and COVID-19: The Complex Interplay of ACE2 and TMPRSS2. Cancer medicine, 2025, 14(7):e70829.

(12)Zhang Yilei, Xie Yuhuan, Wang Yiwen, Huang Panpan*, Lu Yao*. The Role of Radiosensitizing Drugs in Osteosarcoma Treatment: Mechanisms and Clinical Perspectives. Drug design, development and therapy, 2025, 19:1927-1942.

Copyright© 2015 All Rights Reserved. Copyright © 赣南医科大学基础医学院   江西省赣州市开发区高校园区赣南医科大学黄金校区 341000